Two doses of a simple tuberculosis vaccine after surgery support the immune system in fighting cancer cells and could significantly improve treatment outcomes for the most common form of bladder cancer, according to a pilot study involving 40 patients. Initial results of the RUTIVAC-1 study were presented at EAU25.
Autoren
- Birke Dikken
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- How do weight loss interventions affect the muscles?
Reflective evaluation: do not neglect qualitative aspects
- From biomarkers to gene therapies
Getting to know ataxias
- Evidence-based therapy for psoriasis in difficult locations
IL-23 inhibition in scalp psoriasis: what’s new?
- Obesity in the family practice
Aim for realistic goals and avoid apportioning blame
- Evidence, pathophysiology and management in the light of current data
Heart failure with improved ejection fraction (HFimpEF)
- Early rheumatoid arthritis
C1M has potential as a biomarker
- Osteoporosis
Risk-stratified therapy with osteoanabolic agents improves outcomes
- "Swiss Health Care Atlas"